Personalized dosimetry using (131)I-anti-CD45-apamistamab (Iomab-B) prior to high-dose myeloablative radioimmunotherapy for hematopoietic stem cell transplant (HCT) in active, relapsed, or refractory acute myelogenous leukemia: Novel re-induction and targeted conditioning feasibility and engraftment results from the SIERRA trial Meeting Abstract

  

Authors:	Griffeth, L.; Passalaqua, S.; Wiseman, G.; Avril, N.; Yap, W.; Chen, M. K.; Wagner, R.; Natwa, M.; Chasen, B.; Lamonica, D.; Konerth, S.; Fisher, D.; Safavi, F.; Berger, M.; Reddy, V.; Pandit-Taskar, N.
Abstract Title:	Personalized dosimetry using (131)I-anti-CD45-apamistamab (Iomab-B) prior to high-dose myeloablative radioimmunotherapy for hematopoietic stem cell transplant (HCT) in active, relapsed, or refractory acute myelogenous leukemia: Novel re-induction and targeted conditioning feasibility and engraftment results from the SIERRA trial
Meeting Title:	2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Journal Title:	Journal of Nuclear Medicine
Volume:	60
Issue:	Suppl. 1
Meeting Dates:	2019 Jun 22-25
Meeting Location:	Anaheim, CA
ISSN:	0161-5505
Publisher:	Society of Nuclear Medicine
Date Published:	2019-05-01
Language:	English
ACCESSION:	WOS:000473116800433
PROVIDER:	wos
Notes:	Meeting Abstract: 434 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/150856